Viridian Therapeutics宣布，其创新药物Lumvoa™（通用名：veligrotug-vvze）已获得美国食品药品监督管理局（FDA）的批准，并正式上市，用于甲状腺眼病（TED）的治疗。
这一批准标志着Viridian Therapeutics在眼科治疗领域取得了一项重要进展。Lumvoa™是一种针对特定靶点的生物制剂，其获批为甲状腺眼病患者提供了一种新的治疗选择。
甲状腺眼病是一种与甲状腺功能异常相关的自身免疫性疾病，可导致眼球突出、复视、视力受损等一系列症状，严重影响患者的生活质量。新药的上市有望满足该疾病领域未尽的医疗需求。
公司表示，将立即启动Lumvoa™在美国的商业化进程，确保该药物能够尽快惠及有需要的患者。此次获批是基于多项临床研究的数据，这些数据证明了该疗法在改善疾病体征和症状方面的有效性与安全性。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.